牛牛AI助理已提取核心訊息
On January 1, 2024, Sian Bigora, the Chief Development Officer of Processa Pharmaceuticals, Inc. (PCSA), completed a transaction involving the sale of company stock. Bigora disposed of 368 shares of common stock at a price of $2.79 per share, resulting in a total market value of $1,026.72. Following this transaction, Bigora directly holds 21,458 shares of Processa Pharmaceuticals. Additionally, Bigora has an indirect ownership of 6,668 shares through CorLyst, LLC. The transaction reflects a direct dealing by the officer and is part of the normal course of stock trading activities.
On January 1, 2024, Sian Bigora, the Chief Development Officer of Processa Pharmaceuticals, Inc. (PCSA), completed a transaction involving the sale of company stock. Bigora disposed of 368 shares of common stock at a price of $2.79 per share, resulting in a total market value of $1,026.72. Following this transaction, Bigora directly holds 21,458 shares of Processa Pharmaceuticals. Additionally, Bigora has an indirect ownership of 6,668 shares through CorLyst, LLC. The transaction reflects a direct dealing by the officer and is part of the normal course of stock trading activities.
2024年1月1日，Processa Pharmicals, Inc.（PCSA）的首席開發官西安·比戈拉完成了一項涉及出售公司股票的交易。Bigora以每股2.79美元的價格出售了368股普通股，總市值爲1,026.72美元。在這筆交易之後，Bigora直接持有Processa Pharmicals的21,458股股份。此外，Bigora通過CorlyST, LLC間接擁有6,668股股票的所有權。該交易反映了該官員的直接交易，是股票交易活動正常過程的一部分。
2024年1月1日，Processa Pharmicals, Inc.（PCSA）的首席開發官西安·比戈拉完成了一項涉及出售公司股票的交易。Bigora以每股2.79美元的價格出售了368股普通股，總市值爲1,026.72美元。在這筆交易之後，Bigora直接持有Processa Pharmicals的21,458股股份。此外，Bigora通過CorlyST, LLC間接擁有6,668股股票的所有權。該交易反映了該官員的直接交易，是股票交易活動正常過程的一部分。
有用
沒用